US 11,883,480 B2
Formulations of dengue virus vaccine compositions
Michael S. Ryan, Allentown, PA (US); Sherrie-Ann P. Martin, Paoli, PA (US); Jeffrey Thomas Blue, Telford, PA (US); Heidi Joanne Pixley, Glenside, PA (US); Erin J. Green-Trexler, Green Lane, PA (US); and Lynne Ann Isopi, Quakertown, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on Jul. 26, 2022, as Appl. No. 17/815,037.
Application 17/815,037 is a continuation of application No. 16/769,837, abandoned, previously published as PCT/US2018/063541, filed on Dec. 3, 2018.
Claims priority of provisional application 62/595,842, filed on Dec. 7, 2017.
Prior Publication US 2023/0061673 A1, Mar. 2, 2023
Int. Cl. A61K 39/12 (2006.01); A61K 47/42 (2017.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 9/19 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/19 (2013.01); A61K 39/39 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/70 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A formulation that comprises the following components:
a) a live attenuated tetravalent dengue vaccine comprising i) about 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) about 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) about 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) about 100-10,000,000 pfu/ml rDEN4Δ30 virus,
b) about 11 mM potassium phosphate buffer at a pH of about 7.0-8.0,
c) about 90 mg/ml sucrose,
d) about 5 mg/ml propylene glycol,
e) about 5 mg/ml sodium carboxymethylcellulose,
f) about 50 mM NaCl, and
g) about 25 mM Leu.